| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Activity of single-agent gemcitabine as second-line treatment after previous chemotherapy or radiotherapy in advanced non-small-cell lung cancer
|
van Putten, John W.G
|
|
2001
|
33 |
2-3 |
p. 289-298
10 p.
|
artikel
|
| 2 |
Alterations of cell cycle regulators are less frequent in advanced non-small cell lung cancer than in resectable tumours
|
Gugger, M.
|
|
2001
|
33 |
2-3 |
p. 229-239
11 p.
|
artikel
|
| 3 |
A phase I/II trial of cisplatin, docetaxel and ifosfamide in advanced or recurrent non-small cell lung cancer
|
Kunitoh, Hideo
|
|
2001
|
33 |
2-3 |
p. 259-265
7 p.
|
artikel
|
| 4 |
Atypical adenomatous hyperplasia of the lung in autopsy cases
|
Yokose, Tomoyuki
|
|
2001
|
33 |
2-3 |
p. 155-161
7 p.
|
artikel
|
| 5 |
Characterization of human non-small cell lung cancer (NSCLC) cell lines for expression of MHC, co-stimulatory molecules and tumor-associated antigens
|
Wroblewski, Joanne M
|
|
2001
|
33 |
2-3 |
p. 181-194
14 p.
|
artikel
|
| 6 |
Combination of gemcitabine and cisplatin for advanced non-small cell lung cancer: a phase II study with emphasis on scheduling
|
Huisman, C
|
|
2001
|
33 |
2-3 |
p. 267-275
9 p.
|
artikel
|
| 7 |
Contents
|
|
|
2001
|
33 |
2-3 |
p. iii-
1 p.
|
artikel
|
| 8 |
Contents continued
|
|
|
2001
|
33 |
2-3 |
p. iv-
1 p.
|
artikel
|
| 9 |
Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer
|
Marom, Edith M
|
|
2001
|
33 |
2-3 |
p. 99-107
9 p.
|
artikel
|
| 10 |
Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer
|
Rebattu, Paul
|
|
2001
|
33 |
2-3 |
p. 277-287
11 p.
|
artikel
|
| 11 |
Genetic polymorphisms of NAD(P)H quinone oxidoreductase, CYP1A1 and microsomal epoxide hydrolase and lung cancer risk in Nanjing, China
|
Yin, L.
|
|
2001
|
33 |
2-3 |
p. 133-141
9 p.
|
artikel
|
| 12 |
IASLC News: Executive Director & World Co
|
|
|
2001
|
33 |
2-3 |
p. 309-310
2 p.
|
artikel
|
| 13 |
In vitro establishment of cis-diammine-dichloroplatinum(II) resistant lung cancer cell line and modulation of apoptotic gene expression as a mechanism of resistant phenotype
|
Yoon, Sung-Soo
|
|
2001
|
33 |
2-3 |
p. 221-228
8 p.
|
artikel
|
| 14 |
Is there a role of platelet-activating factor in human lung cancer?
|
Denizot, Y.
|
|
2001
|
33 |
2-3 |
p. 195-202
8 p.
|
artikel
|
| 15 |
Lung cancer in patients under 50 years old
|
Radzikowska, Elżbieta
|
|
2001
|
33 |
2-3 |
p. 203-211
9 p.
|
artikel
|
| 16 |
Phase I and pharmacologic study of sequential topotecan, carboplatin, and etoposide
|
Miller, Antonius A
|
|
2001
|
33 |
2-3 |
p. 241-248
8 p.
|
artikel
|
| 17 |
Prognostic significance of flow cytometric DNA analysis in patients with malignant pleural mesothelioma
|
Emri, Salih
|
|
2001
|
33 |
2-3 |
p. 109-114
6 p.
|
artikel
|
| 18 |
Pronostic factors of synchronous brain metastases from lung cancer
|
Penel, Nicolas
|
|
2001
|
33 |
2-3 |
p. 143-154
12 p.
|
artikel
|
| 19 |
Radiation recall reaction following gemcitabine
|
Fogarty, Gerald
|
|
2001
|
33 |
2-3 |
p. 299-302
4 p.
|
artikel
|
| 20 |
Reflexions from the experience of the French CLEOPATRE program and concerns about the status of clinical research on small cell lung cancer
|
Trillet-Lenoir, Veronique
|
|
2001
|
33 |
2-3 |
p. 303-307
5 p.
|
artikel
|
| 21 |
Serum anti-p53 antibodies in lung cancer: comparison with established tumor markers
|
Cioffi, M
|
|
2001
|
33 |
2-3 |
p. 163-169
7 p.
|
artikel
|
| 22 |
Ten-year follow-up of Southwest Oncology Group 8269: a phase II trial of concomitant cisplatin–etoposide and daily thoracic radiotherapy in limited small-cell lung cancer
|
Thomas Jr., Charles R
|
|
2001
|
33 |
2-3 |
p. 213-219
7 p.
|
artikel
|
| 23 |
Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B study
|
Graziano, Stephen L
|
|
2001
|
33 |
2-3 |
p. 115-123
9 p.
|
artikel
|
| 24 |
Using treatment interruptions to palliate the toxicity from concurrent chemoradiation for limited small cell lung cancer decreases survival and disease control
|
Videtic, Gregory M.M
|
|
2001
|
33 |
2-3 |
p. 249-258
10 p.
|
artikel
|
| 25 |
Vascular endothelial growth factor and other biological predictors related to the postoperative survival rate on non-small cell lung cancer
|
Liao, Meilin
|
|
2001
|
33 |
2-3 |
p. 125-132
8 p.
|
artikel
|
| 26 |
Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leukocyte counts
|
Choi, Jin-Hyuk
|
|
2001
|
33 |
2-3 |
p. 171-179
9 p.
|
artikel
|
Tijdschrift beschrijving